2020 ttf alk session qa panel progression on 2nd-gen alk inhibitor if biopsy shows no alk mutation
Published 3 years ago • 13 plays • Length 3:06Download video MP4
Download video MP3
Similar videos
-
23:44
2020 ttf alk session raez sequence of alk inhibitors
-
2:34
2020 ttf alk session qa panel next steps after progression on lorlatinib
-
2:16
2020 ttf alk session qa panel ros1 patients on immunotherapy chemotherapy combinations
-
3:46
2020 ttf alk session qa panel the use of an alk tki post chemoradiation for stage 3b lung cancer
-
1:43
2020 ttf alk session qa panel reducing dosage on lorlatinib vs switching to a different agent
-
1:50
2020 ttf alk/ros session qa panel the difference in efficacy of tkis in different patients
-
2:16
2020 ttf alk session qa panel using ctc profiling to detect crizotinib resistance on progression
-
4:08
2020 ttf alk/ros session qa panel treatment decisions for simultaneous egfr and ros1 mutation
-
2:28
2020 ttf alk session qa panel the future of mek inhibitors
-
2:36
2020 ttf alk session qa panel information on the crown trial and firstline lorlatinib
-
25:07
2020 ttf alk session - lin - tkis for ros1
-
4:20
video 2020 ttf alk/ros session qa panel the efficacy of dose reduction or interruption of crizotinib
-
1:57
video 2020 ttf alk/ros session qa panel ros1 patients - chemo after resistance to inhibitor therapy?
-
3:24
2020 ttf alk qa panel ros1 clinical trial updates
-
1:20
2020 ttf alk/ros session qa panel ros1 patient on crizotinib, brain metastases treated with srt
-
10:45
case based panel discussion 2.3 developing resistance to alk inhibitors, areas of progression after
-
7:41
gracecast - lcvl - h. jack west md - can alk inhibitors treat and prevent brain metastases
-
9:59
case based panel discussions - alk positive, developing resistance to alk inhibitors and next steps